Early Phase Trials and Sarcoma Unit, Institut Bergonié, Bordeaux, France.
DITEP, Gustave Roussy, Villejuif, France.
Cancer Discov. 2023 Aug 4;13(8):1765-1767. doi: 10.1158/2159-8290.CD-23-0605.
Murine double minute 2 (MDM2) inhibitors represent an opportunity to target p53 in solid tumors with wild-type TP53 and particularly in some sarcomas characterized by a consistent amplification of the MDM2 gene. In this issue of Cancer Discovery, LoRusso and colleagues and Koyama and colleagues report the results of two early-phase studies investigating two different TP53-MDM2 antagonists in patients with soft-tissue sarcomas and other solid tumors. See related article by LoRusso et al., p. 1802 (5) . See related article by Koyama et al., p. 1814 (8) .
鼠双微体 2 (MDM2) 抑制剂为靶向野生型 TP53 实体肿瘤中的 p53 提供了机会，特别是在一些肉瘤中，这些肉瘤的 MDM2 基因经常被扩增。在本期《Cancer Discovery》中，LoRusso 及其同事和 Koyama 及其同事报告了两项早期研究的结果，这两项研究调查了两种不同的 TP53-MDM2 拮抗剂在软组织肉瘤和其他实体肿瘤患者中的应用。见 LoRusso 等人的相关文章，第 1802 页（5）。见 Koyama 等人的相关文章，第 1814 页（8）。
